IBD in the time of corona - vigilance for immune-mediated diseases

Nat Rev Gastroenterol Hepatol. 2020 Sep;17(9):529-530. doi: 10.1038/s41575-020-0333-5.


The gastrointestinal tract represents a target organ for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), warranting a thorough discussion on the consequences, particularly regarding inflammatory bowel diseases. Here, aspects of gastrointestinal involvement with SARS-CoV-2, the role of viruses as modulators of mucosal immunity and as treatment-related safety hazards, and the current clinical evidence will be discussed.

Trial registration: ClinicalTrials.gov NCT04276688 NCT04354259.

Publication types

  • Review

MeSH terms

  • Betacoronavirus*
  • COVID-19
  • Coronavirus Infections / complications*
  • Coronavirus Infections / epidemiology
  • Coronavirus Infections / immunology
  • Humans
  • Immunity, Mucosal*
  • Inflammatory Bowel Diseases / complications*
  • Inflammatory Bowel Diseases / immunology
  • Pandemics
  • Pneumonia, Viral / complications*
  • Pneumonia, Viral / epidemiology
  • Pneumonia, Viral / immunology
  • SARS-CoV-2

Associated data

  • ClinicalTrials.gov/NCT04276688
  • ClinicalTrials.gov/NCT04354259